Lantheus initiated with an Outperform at TD Cowen

TD Cowen analyst Boris Peaker initiated coverage of Lantheus with an Outperform rating and $100 price target. A “market leader” in precision diagnostics with key products targeting prostate cancer and cardiovascular disease, Lantheus has multiple collaborations and a rich pipeline that should drive long-term growth, says the analyst, who identifies PNT2002 data due in Q4 as a key upcoming catalyst.